We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 84.00 | 0.75% | 11,352.00 | 11,350.00 | 11,352.00 | 11,412.00 | 11,288.00 | 11,288.00 | 3,579,740 | 16:29:59 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 29.55 | 175.98B |
From Apr 2019 to Apr 2024
By Anthony O. Goriainoff
AstraZeneca PLC said on Monday that its Lynparza drug has been recommended for approval in the European Union as first-line maintenance treatment for HRD-positive advanced ovarian cancer, and that it has also been recommended for marketing authorization by the EU for patients with metastatic castration-resistant prostate cancer.
The FTSE 100-listed drug maker also said that results from a prespecified exploratory analysis of the positive ADAURA phase 3 trial showed its Tagrisso drug demonstrated a clinically-meaningful improvement in central nervous system disease-free survival in patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection. The company said Tagrisso also reduced the risk of disease recurrence in the brain by 82% in the adjuvant treatment of early-stage epidermal growth factor receptor-mutated lung cancer.
The company said that advanced ovarian cancer patients treated with Lynparza and drug bevacizumab lived without disease progression for a median of 37.2 months versus 17.7 months for bevacizumab alone.
The pharmaceutical company also said that for patients with advanced ovarian cancer, the primary aim of first-line treatment is to delay disease progression for as long as possible with the intent to achieve long-term remission.
Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
September 21, 2020 02:47 ET (06:47 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
